XML 74 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense Amounts recognized in the financial statements with respect to stock-based compensation programs, which include stock options, restricted stock, restricted stock units, performance shares and the General Employees’ Stock Purchase Plan (GESPP), are provided in the following table. Capitalized stock-based compensation amounts were not material.
(Millions)202420232022
Cost of sales$39 $38 $42 
Selling, general and administrative expenses185 165 153 
Research, development and related expenses44 38 39 
Stock-based compensation expenses268 241 234 
Income tax benefits(31)(41)(58)
Stock-based compensation expenses (benefits), net of tax$237 $200 $176 
Schedule of Stock Option Activity The following table summarizes stock option activity:
(Options in thousands)Number of OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual Life (months)Aggregate Intrinsic Value (millions)
Under option —
As of January 1, 2024
34,683 $167.38 
Expired(3,689)130.83 
Solventum exits(2,558)169.45 
Share conversion3,942 151.08 
Granted528 97.15 
Exercised(218)120.80 
Forfeited(165)123.91 
As of December 31, 2024
32,523 150.50 43$55 
Options exercisable
As of December 31, 2024
29,959 $153.29 39$12 
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award
The following table summarizes additional information relative to stock options exercised during the respective years:
(in millions)202420232022
Cash received from options exercised$26 $147 $205 
Intrinsic value of options exercised3 29 116 
Tax benefit realized related to options exercised1 24 
The following table summarizes additional information relative to restricted stock units for the respective years:
(in millions, except per-unit amounts)202420232022
Weighted-average grant-date fair value of restricted stock units (per unit) that were granted$98.01 $114.71 $160.24 
Intrinsic value of restricted stock units that vested73 81 88 
Tax benefit realized related to restricted stock units that vested14 16 17 
The following table summarizes additional information relative to performance shares for the respective years:
(in millions, except per-share amounts)202420232022
Weighted average grant date fair value per performance share that were granted$97.82 $110.21 $144.77 
Intrinsic value of performance shares that were distributed9 19 21 
Tax benefit realized related to performance shares that were distributed2 
Schedule of Stock Option Assumptions
For the primary annual stock option grant, the weighted average fair value at the date of grant was calculated using the Black-Scholes option-pricing model and the assumptions that follow.
2024
20232022
Exercise price$97.15 $116.90 $162.41 
Risk-free interest rate4.4 %3.8 %1.9 %
Dividend yield3.8 %3.3 %2.9 %
Expected volatility24.6 %22.8 %21.8 %
Expected life (months)958483
Black-Scholes fair value$20.53 $22.22 $25.34 
Schedule of Restricted Stock Units Activity The following table summarizes restricted stock unit activity:
(Units in thousands)Number of UnitsWeighted Average Grant Date Fair Value
Nonvested balance —
As of January 1, 2024
3,798 $136.55 
Vested(737)163.69 
Solventum exits(815)122.38 
Share conversion328 115.54 
Granted4,001 98.01 
Forfeited(425)109.27 
As of December 31, 2024
6,150 104.83 
Schedule of Performance Shares Activity
The following table summarizes performance share activity:
(Shares in thousands)Number of SharesWeighted Average Grant Date Fair Value
Undistributed balance —
As of January 1, 2024
360 $136.95 
Vested(101)176.72 
Solventum Exits(3)144.75 
Share conversion51 113.35 
Granted338 97.82 
Performance change240 100.86 
Forfeited(103)102.67 
As of December 31, 2024
782 101.99